scPharmaceuticals Announces Expansion of Executive Team

“scPharmaceuticals is honored and excited to welcome Mr. Ceesay and Mr.    Ignelzi at this important time in the company as we prepare to file our first new    drug application and position the company for successful product introductions in    2017,” said Pieter Muntendam, President, CEO and a member of its board of    directors. “We stand to benefit tremendously from their extensive, on-point    experience in similarly staged biotech and pharmaceutical companies. I look forward    to collaborating with Troy and Abe as they take on their new roles and help ensure    the smooth, successful growth of the Company.”

“The scPharmaceuticals product platform and sc2Wear device represent    innovative and disruptive solutions for the treatment of Heart Failure and Infectious    Disease. This platform was developed to reduce the cost of care and improve quality    for serious conditions that are economically burdensome to the health care    system,” said Abe Ceesay, Chief Operating Officer. “I am excited to lead    the commercial and operational efforts for the company and these important products    that help payors and providers meet their economic goals and quality objectives,    while improving the lives of patients.”

“Innovations in life sciences generally increase the cost of care,”    said Troy Ignelzi, Chief Financial Officer. “With increasing concerns over the    rising costs of healthcare, scPharmaceuticals offers an exciting opportunity for    creating shareholder value by introducing innovative products that improve care    processes and reduce the economic burden for all.”

About Mr. Abraham Ceesay

Mr. Ceesay brings extensive experience in the launch and growth of innovative    therapeutic products and a strong track record in leading global commercial teams and    development-oriented organizations to commercial stage companies. Prior to joining    scPharmaceuticals, Mr. Ceesay served as Vice President, Sales, Marketing, and    Commercial Operations at Keryx Biopharmaceuticals where he developed the commercial    organization and strategy for the company’s inaugural product Auryxia®.    Prior to his career at Keryx, Mr. Ceesay spent four years at Ironwood Pharmaceuticals    as Vice President, Marketing, where he led the launch of the company’s    inaugural product Linzess® and held responsibility for the management of the U.S.    P&L, leadership of the Linzess® brand team and co-promotion collaboration    with Forest Laboratories/Allergan. Mr. Ceesay also spent eight years at    Genzyme/Sanofi, initially as a field sales specialist and ultimately as the Director,    Renal Global Marketing, in which capacity he led the global launch of Renvela®    and held global marketing responsibility for the company’s renal franchise    (Renagel®, Renvela®, Hectorol®). Mr. Ceesay holds a bachelor’s    degree from Ithaca College, and a Masters of Business Administration from Suffolk    University’s Sawyer School of Management.

About Mr. Troy Ignelzi

Mr. Ignelzi brings to scPharmaceuticals over 20 years of experience in finance,    operations and business development with startups and established life sciences    companies. He joins the Company from Juventas Therapeutics as Chief Financial Officer    where he successfully completed venture debt and equity financings. Prior to    Juventas, he was Senior Vice President of Operations and Business Development at YES    Group, in a consulting capacity. In addition to global business development, he was    responsible for financing engagements and provided strategic guidance to multiple    clients’ SEC filings and subsequent successful IPOs. He held executive    management positions at Esperion Therapeutics and Insys Therapeutics — two    startups that eventually became publicly traded companies. He has helped raise over    $300 million through both private placements and IPOs, licensed therapeutics and    provided operational leadership to advance multiple therapeutic platforms through key    clinical development milestones.

About scPharmaceuticals:
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical    company developing a portfolio of transformative pharmaceutical products for    subcutaneous delivery. Based on widely used generic drugs that currently require    intravenous or intramuscular injections, our innovative products will be    administered subcutaneously via a proprietary patch pump. This avoids material    risks and costs associated with the current delivery options. Our lead products    are the first subcutaneous formulations of furosemide (the most widely used    parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used    parenteral antibiotic outside the hospital setting). Our novel furosemide    formulation enables convenient anytime anywhere use, for example in an outpatient    setting instead of the emergency room or other in-patient settings. For    ceftriaxone and other antibiotics, subcutaneous administration eliminates the need    for PICCs (peripherally inserted central catheters), which are associated with    serious complications, frequent adverse events and high medical cost.

For More Information:
Katherine Taudvin
Director, Corporate Development
Email: ktaudvin@scpharma.com
Telephone: (781) 301-6706